Movement Disorders (revue) - Exploration (Accueil)

Index « Mesh.i » - entrée « Receptors, N-Methyl-D-Aspartate »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Receptors, Muscarinic < Receptors, N-Methyl-D-Aspartate < Receptors, Nerve Growth Factor  Facettes :

List of bibliographic references indexed by Receptors, N-Methyl-D-Aspartate

Number of relevant bibliographic references: 22.
[0-20] [0 - 20][0 - 22][20-21][20-40]
Ident.Authors (with country if any)Title
000504 (2014) Yael Hacohen [Royaume-Uni] ; Kumaran Deiva ; Phillipa Pettingill ; Patrick Waters ; Ata Siddiqui ; Pascale Chretien ; Esse Menson ; Jean-Pierre Lin ; Marc Tardieu ; Angela Vincent ; Ming J. LimN-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse.
000561 (2014) Shekeeb S. Mohammad [Australie] ; Kate Sinclair ; Sekhar Pillai ; Vera Merheb ; Tim D. Aumann ; Deepak Gill ; Russell C. Dale ; Fabienne BrilotHerpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-Methyl-D-aspartate receptor or dopamine-2 receptor.
000662 (2014) Maarten J. Titulaer [Pays-Bas] ; Frank Leypoldt ; Josep DalmauAntibodies to N-methyl-D-aspartate and other synaptic receptors in choreoathetosis and relapsing symptoms post-herpes virus encephalitis.
000728 (2013) José Fidel Baizabal-Carvallo [États-Unis] ; Amber Stocco ; Eyal Muscal ; Joseph Jankovic [États-Unis]The spectrum of movement disorders in children with anti-NMDA receptor encephalitis.
000876 (2013) Lorraine V. Kalia [Canada] ; Jonathan M. Brotchie ; Susan H. FoxNovel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials.
000971 (2013) Uriel Heresco-Levy [Israël] ; Shai Shoham ; Daniel C. JavittGlycine site agonists of the N-methyl-D-aspartate receptor and Parkinson's disease: a hypothesis.
000C94 (2012) Paolo Calabresi [Italie] ; Massimiliano Di Filippo [Italie] ; Antongiulio Gallina [Italie] ; Yingfei Wang [États-Unis] ; Jeannette N. Stankowski [États-Unis] ; Barbara Picconi [Italie] ; Valina L. Dawson [États-Unis] ; Ted M. Dawson [États-Unis]New Synaptic and Molecular Targets for Neuroprotection in Parkinson’s Disease
001602 (2011) Ignacio Rubio-Agustí [Espagne] ; Josep Dalmau [États-Unis] ; Teresa Sevilla [Espagne] ; María Burgal [Espagne] ; Eduardo Beltrán [Espagne] ; Luís Bataller [Espagne]Isolated hemidystonia associated with NMDA receptor antibodies
001706 (2011) Jee-Young Lee [Corée du Sud] ; Jinwhan Cho [Corée du Sud] ; Eun-Kyung Lee [Corée du Sud] ; Sung-Sup Park [Corée du Sud] ; Beom S. Jeon [Corée du Sud]Differential genetic susceptibility in diphasic and peak‐dose dyskinesias in Parkinson's disease
002090 (2009) Hiroshi Kataoka [Japon] ; Josep Dalmau [États-Unis] ; Toshiaki Taoka [Japon] ; Satoshi Ueno [Japon]Reduced N‐acetylaspartate in the basal ganglia of a patient with anti‐NMDA receptor encephalitis
002446 (2009) Jee-Young Lee [Corée du Sud] ; Eun Kyung Lee [Corée du Sud] ; Sung Sup Park [Corée du Sud] ; Ji-Yeon Lim [Corée du Sud] ; Hee Jin Kim [Corée du Sud] ; Ji Sun Kim [Corée du Sud] ; Beom S. Jeon [Corée du Sud]Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease
003245 (2006) Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada]Prevention of levodopa‐induced dyskinesias by a selective NR1A/2B N‐methyl‐D‐aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin
003584 (2006) Rivka Inzelberg [Israël] ; Ubaldo Bonuccelli [Italie] ; Edna Schechtman [Israël] ; Ala Miniowich [Israël] ; Rosa Strugatsky [Israël] ; Roberto Ceravolo [Italie] ; Chiara Logi [Italie] ; Carlo Rossi [Italie] ; Colin Klein [Israël] ; J. Martin Rabey [Israël]Association between amantadine and the onset of dementia in Parkinson's disease
004085 (2003) Juha-Matti Savola [Finlande] ; Michael Hill [Royaume-Uni] ; Mia Engstrom [Finlande] ; Hannele Merivuori [Finlande] ; Siegfried Wurster [Finlande] ; Steven G. Mcguire [Royaume-Uni] ; Susan H. Fox [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni, Canada]Fipamezole (JP‐1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson's disease
004544 (2002) Joanne E. Nash [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni]Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: Intrastriatal microinjection studies in the 6‐OHDA‐lesioned rat
004771 (2001) Paolo Del Dotto [Italie] ; Nicola Pavese [Italie] ; Gianna Gambaccini [Italie] ; Silvia Bernardini [Italie] ; Leonard Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Ubaldo Bonuccelli [Italie]Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study
004A02 (2000) Leo Verhagen Metman [États-Unis] ; Spiridon Konitsiotis [États-Unis] ; Thomas N. Chase [États-Unis]Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what
005079 (1998) Pierre J. Blanchet [États-Unis] ; Spyridon Konitsiotis [États-Unis] ; Thomas N. Chase [États-Unis]Amantadine reduces levodopa‐induced dyskinesias in parkinsonian monkeys
005724 (1996) Kieburtz [États-Unis] ; Andrew Feigin [États-Unis] ; Michael Mcdermott [États-Unis] ; Peter Como [États-Unis] ; David Abwender [États-Unis] ; Carol Zimmerman [États-Unis] ; Charlyne Hickey [États-Unis] ; Constance Orme [États-Unis] ; Kathy Claude [États-Unis] ; Jennie Sotack [États-Unis] ; J. Timothy Greenamyre [États-Unis] ; Cynthia Dunn [États-Unis] ; Ira Shoulson [États-Unis]A controlled trial of remacemide hydrochloride in Huntington's disease
005A54 (1994) M B YoudimParkinson's disease and milacemide.
005B25 (1994) J. L. Montastruc [France] ; N. Fabre [France] ; Olivier Rascol [France] ; J. M. Senard [France] ; O. Blin [France]N‐methyl‐D‐aspartate (NMDA) antagonist and Parkinson's disease: A pilot study with dextromethorphan

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i -k "Receptors, N-Methyl-D-Aspartate" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i  \
                -Sk "Receptors, N-Methyl-D-Aspartate" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Receptors, N-Methyl-D-Aspartate
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024